Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy
AKT2
DOI:
10.1016/j.ymthe.2023.07.021
Publication Date:
2023-07-28T01:13:27Z
AUTHORS (22)
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to immune checkpoint blockade therapy, and negative feedback of tumor evasion might be partly responsible. We isolated CD8+ T cells cultured them in vitro. Proteomics analysis was performed compare changes Panc02 cell lines with conditioned medium, leucine-rich repeat kinase 2 (LRRK2) identified as a differential gene. LRRK2 expression related spatial distribution PDAC clinical samples upregulated by via interferon gamma (IFN-γ) simulation Knockdown or pharmacological inhibition activated an anti-pancreatic cancer response mice, which meant that acted immunosuppressive Mechanistically, phosphorylated PD-L1 at T210 inhibit its ubiquitination-mediated proteasomal degradation. attenuated PD-1/PD-L1 blockade-mediated, cell-induced upregulation LRRK2/PD-L1, thus sensitizing the mice anti-PD-L1 therapy. In addition, adenosylcobalamin, form vitamin B12, found broad-spectrum inhibitor LRRK2, could vivo sensitize immunotherapy well, potentially endows translational value. Therefore, combined novel therapy strategy for PDAC.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (51)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....